Cantor Fitzgerald initiated coverage of Capricor Therapeutics with an Overweight rating and $8 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAPR:
- Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
- Capricor Therapeutics announces continuation of Phase 3 HOPE-3 trial
- Capricor Therapeutics reports Q3 EPS (25c), consensus (29c)
- Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
- Is CAPR a Buy, Before Earnings?